Merck’s acquiring Terns Pharmaceuticals in $6.7bn transaction
Multinational pharma group Merck has reached a definitive agreement to acquire pharmaceutical research company Terns Pharmaceuticals in a transaction valued at approximately $6.7bn. This move is widely viewed as a strategic manoeuvre to bolster Merck’s oncology and haematology pipeline as the company prepares for the anticipated loss of exclusivity for its blockbuster cancer therapy, Keytruda, later this decade. The primary…